This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Dow Component Johnson & Johnson (JNJ) To Go Ex-dividend

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

The
Dow Jones Industrial Average (
^DJI) is trading up 18 points (+0.1%) at 12,806 as of Wednesday, Nov 21, 2012, 10:35 a.m. ET. During this time, 147.2 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 615.8 million. The NYSE advances/declines ratio sits at 1,583 issues advancing vs. 1,198 declining with 164 unchanged.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Friday, November 23, 2012 is the ex-dividend date for Dow component
Johnson & Johnson (NYSE:
JNJ). Owners of shares as of market close today will be eligible for a dividend of 61 cents per share. At a price of $69.62 as of 10:36 a.m. ET, the dividend yield is 3.5% compared to the average Dow component yield of 2.9%.

The average volume for Johnson & Johnson has been 11.2 million shares per day over the past 30 days. Johnson & Johnson has a market cap of $191.91 billion and is part of the health care sector and drugs industry. Shares are up 6.2% year to date as of Tuesday's close.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company has a P/E ratio of 22.7, equal to the average drugs industry P/E ratio.

TheStreet Ratings rates Johnson & Johnson as a
buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.